Novo Nordisk spies great hemophilia opportunities with partner Genmab

Pharmaceutical firm Novo Nordisk is expecting to send a new hemophilia drug to the market in 2025. It might end up being one of the best, according to Novo exec Martin Holst Lange.

Martin Holst Lange, executive vice president of development at Novo Nordisk | Photo: Novo Nordisk / PR

Novo Nordisk’s lucrative biopharma arm has stopped hemorrhaging, but growth is still a way away following years of this being the status quo. The hemophilia treatment Mim8 could speed up this process.

”It is more potent than other drugs, including Hemlibra. That means it could potentially be given in smaller volumes in better devices,” says Martin Holst Lange, executive vice president of development at Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs